|  |
| --- |
| **Supplemental Table 1:** Sensitivity of TST vs. QFT compared to a composite reference standard of either positive test for LTBI diagnosis in HIV-infected women by peripartum stage |
|  | **Pregnancy (n=96)** | **Postpartum (n=91a)** |  |
| **LTBI diagnostic test** | Positive among totalN=96 (%) | Positive among LTBIbN=36 (%) | Sensitivity %(95% CI) | Positive among totalN=91 (%) | Positive among LTBIbN=36 (%) | Sensitivity %(95% CI) | *Pregnancy vs. postpartum sensitivity* *pc* |
| Either TST+ or QFT+ (reference standard) | 36 | 37.5 | 36 | 100.0 |  - |  - | 36 | 39.6 | 36 | 100.0 |  - |  - |  |
| TST+  | 13 | 13.5 | 13 | 36.1 | 36.1 | 20.8-53.8 | 22 | 24.2 | 22 | 61.1 | 61.1 | 43.5-76.9 |  **0.02** |
| QFT+  | 33 | 34.4 | 33 | 91.7 | 91.9 | 78.1-98.3 | 34 | 37.4 | 34 | 94.4 | 94.4 | 81.3-99.3 |  0.26 |
| ***Pregnancy TST vs. QFT sensitivity p*=0.0001** | ***Postpartum TST vs. QFT sensitivity p*=0.003** |  |
| aIncludes 81 women retested with QFT/TST postpartum and 10 QFT+/TST+ in pregnancy not retested assumed to remain QFT+/TST+ postpartumbLTBI as measured by either TST+ or QFT+cMcNemar's chi-squared*Abbreviations:* TST, tuberculin skin test; QFT, QuantiFERON® TB Gold In-tube; LTBI, latent tuberculosis infection  |

|  |
| --- |
| **Supplemental Table 2:** TST and QFT results and concordance for LTBI diagnosis in HIV-infected women in western Kenya by pregnancy stage  |
|  | TST positive, n (%) | TST negative, n (%) | Total | Overall Agreement  | kappa (95% CI) |
| **Tested in Pregnancy, n=96a** |  |  |  |  |  |
| QFT positive, n (%) | 10 (10.4) | 23 (24.0) | 33 (34.4) |  |  |
| QFT negative, n (%) | 2 (2.1) | 47 (49.0) | 49 (51.0) |  |  |
| QFT indeterminate, n (%) | 1 (1.0) | 13 (13.5) | 14 (14.6) |  |  |
| Total | 13 (13.5) | 83 (86.5) | 96 (100.0) |  |  |
|  | 56.9% | 0.20 (0.16 - 0.24) |
| **Retested Postpartum, n=81b** |  |  |  |  |
| QFT positive, n (%) | 10 (12.4) | 14 (17.3) | 24 (29.6) |  |  |
| QFT negative, n (%) | 2 (2.5) | 55 (67.9) | 57 (70.4) |  |  |
| QFT indeterminate, n (%) | - | - | - |  |  |
| Total | 12 (14.8) | 69 (85.2) | 81 (100.0) |  |  |
|  | 80.3% | 0.44 (0.23 - 0.66) |
| **Retested Postpartum plus QFT+/TST+ in pregnancy not retested, n=91c** |
| QFT positive, n (%) | 20 (22.0) | 14 (15.4) | 34 (28.4) |  |  |
| QFT negative, n (%) | 2 (2.2) | 55 (60.4) | 57 (71.6) |  |  |
| QFT indeterminate, n (%) | - | - | - |  |  |
| Total | 22 (24.2) | 69 (75.8) | 91 (100.0) |  |  |
|  | 82.4% | 0.60 (0.42 - 0.77) |
| a Excludes 4 women without TST in pregnancy resultsb Excludes 10 women with QFT+/TST+ in pregnancy not retested postpartum per protocol, 2 women lost to follow up, and 7 with either QFT or TST missing (2 QFT missing, 5 TST missing) c Includes 81 women retested with QFT/TST postpartum and 10 QFT+/TST+ in pregnancy not retested assumed to remain QFT+/TST+ postpartum |

|  |
| --- |
| **Supplemental Table 3:** Comparison of antenatal and postpartum QFT/TST testing among HIV-infected peripartum women who underwent IGRA/TST testing in both pregnancy and postpartum, N=78a |
|  | **Postpartum results (6 weeks)** |
| **Pregnancy results** | QFT+/TST+, n (%) | QFT-/TST-,n (%) | QFT+/TST-,n (%) | QFT-/TST+,n (%) |
| QFT-/TST-, n (%)  | 1 (1.3) | 41(52.5) | 2 (2.6) | 0 (0) |
| QFT+/TST-, n (%) | 8 (10.3) | 1 (1.3) | 10 (12.8) | 1 (1.3) |
| QFT-/TST+, n (%) | 0 (0) | 1 (1.3) | 0 (0) | 1 (1.3) |
| QFT indeterminate/TST+ n (%) | 0 (0) | 1 (1.3) | 0 (0) | 0 (0) |
| QFT indeterminate/TST- n (%) | 0 (0) | 9 (11.5) | 2 (2.6) | 0 (0) |
| aOf 100 women enrolled: 10 women with QFT+/TST+ in pregnancy were not retested postpartum per protocol, 2 women were lost to follow up, 4 did not have antenatal TST read. Of 88 women remaining eligible for postpartum testing: 2 did not have QFT performed (1 with postpartum TST+, 1 with postpartum TST+), 5 did not have postpartum TST read (2 with negative QFT postpartum, 3 with positive QFT postpartum), 3 only had TST results available postpartum.  |

|  |
| --- |
| **Supplemental Table 4:** Correlates of TST and QFT positivity by pregnancy stage. |
|  | **Pregnancy** | **Postpartum** |
| Correlate | **TST+** | **QFT+**  | **TST+** | **QFT+**  |
|  | ORa | 95% CI | *p* | ORb | 95% CI | *p* | ORc | 95% CI | *p* | ORd | 95% CI | *p* |
| Age (years)  | 0.98 | 0.89-1.08 | 0.69 | 1.08 | 1.01-1.16 | **0.04** | 1.13 | 1.01-1.25 | **0.03** | 1.09 | 1.01-1.17 | **0.03** |
| Gestational age (weeks)  | 0.91 | 0.83-0.99 | **0.03** | 0.98 | 0.92-1.04 | 0.57 | 1.06 | 0.96-1.17 | 0.24 | 1.01 | 0.94-1.09 | 0.72 |
| ART prior to pregnancy  | 3.64 | 1.01-13.18 | **0.05** | 4.07 | 1.67-9.95 | **0.002** | 5.18 | 1.43-18.79 | **0.01** | 2.75 | 1.05-7.15 | **0.04** |
| TB exposure | 0.23 | 0.03-1.88 | 0.17 | 1.70 | 0.65-4.41 | 0.28 | 2.50 | 0.71-8.83 | 0.16 | 2.57 | 0.93-7.11 | 0.07 |
| Household TB contact  | 0.87 | 0.17-4.37 | 0.87 | 2.15 | 0.72-6.37 | 0.17 | 5.45 | 1.39-21.3 | **0.02** | 3.00 | 1.00-7.76 | 0.06 |
| a Compared to pregnant women with negative TSTb Compared to pregnant women with negative QFT c Compared to postpartum women with negative TSTd Compared to postpartum women with negative QFT |